Advances in clinical immunotherapy combined with targeted therapy for hepatocellular carcinoma
Hepatocellular carcinoma(HCC)is the fourth most common malignant tumor in China and has a serious impact on the quality of life of Chinese people.With the in-depth study of proteomics and the deepening understanding of tumor molecular signaling pathways and microenvironment,new therapeutic means targeted therapy and immunotherapy have gradually become a hot spot.These treatments can improve the prognosis of patients with advanced HCC,but the efficacy is limited.In recent years,studies have shown that immunotherapy combined with targeted therapy can enhance the efficacy of monotherapy.At present,the main combined treatment strategies include immunotherapy combined with targeted therapy,dual combined immunotherapy,and targeted local minimally-invasive combined therapy,among which immunotherapy combined with targeted therapy is the most widely used.In this paper,9 different immunotherapy combined with targeted therapy strategies were compared,all of which can improve the survival of patients,provide a variety of options for patients with liver cancer,and also provide a new idea for the selection of drugs for future combination treatment strategies.
万方数据
维普
